IKNA News and Press, Ikena Oncology Inc. From 08/10/23

Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by year end 2023 Underwritten public offering and acquisition of Pionyr add over $80M...

2023-08-07 14:32:38 ET More on Ikena Oncology Ikena: AACR2023 Validates Their Hippo Pathway Target, But We Need Data Ikena Oncology prices $40M offering Ikena Oncology prices $40M offering Ikena gains on FDA’s fast track status for bladder cancer candi...

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, ...

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in TD Cowen’s 4th Annual Oncology Innovation Summit ...

2023-05-18 03:56:32 ET Summary Ikena is a pioneering developer of molecules targeting the Hippo pathway. This year's AACR showcased a number of programs, one of which showed this to be a druggable pathway. However, IKNA itself needs to show clinical data. Ikena Oncol...

2023-05-15 12:26:37 ET Ikena Oncology press release ( NASDAQ: IKNA ): Q1 GAAP EPS of -$0.39 beats by $0.08 . Revenue of $5.3M (+56.8% Y/Y) beats by $0.68M . For further details see: Ikena Oncology GAAP EPS of -$0.39 beats by $0.08, revenue of $5.3M beats ...

2023-05-15 10:19:06 ET Ikena Oncology ( NASDAQ: IKNA ) prices an underwritten offering of 6.11M shares at an offering price of $6.55 per share. The gross proceeds are expected to be ~$40M. The offering is expected to close on or about May 17, 2023. Net proceeds tog...

Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date Preclinical data at AACR Annual Meeting demonstrated IK-930 TEAD1 selectivity with equivalent activity to panTEAD inhibition and signif...

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced today the pricing of an underwritten offering of 6,110,000 shares of...

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in one-on-one investor m...